Cartesian Therapeutics, Inc.
RNAC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 49.6% | -76.5% | 30.2% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 98.2% | 100% |
| EBITDA | -$0 | -$0 | $0 | -$0 |
| % Margin | -195.3% | -903.8% | 36% | -6.1% |
| Net Income | -$0 | -$0 | $0 | -$0 |
| % Margin | -199% | -844.9% | 31.9% | -30.2% |
| EPS Diluted | -3.29 | -49.76 | 3 | -6.6 |
| % Growth | 93.4% | -1,758.7% | 145.5% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |